옵션 체인은 다양한 행사가격과 만기일에 대한 Kura Sushi USA의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Kura Sushi USA에 대한 시장 심리를 평가합니다..

Kura Sushi USA (NASDAQ:KRUS) 주식, 옵션 체인

Kura Sushi USA

Kura Sushi USA Inc is a technology-enabled restaurant concept serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. It offers several dishes, including Dashi Olive Salmon, Tomago, Sweet Shrimp, Tuna, Garlic Tuna Steak, and Salmon, among others.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ICCC

KRUS

MANU

PSMT

수요일 오전(미 동부 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:

수요일 주목해야 할 주식: 맨체스터 유나이티드, 프라이스스마트, 쿠라 스시 그리고 2종목

CRWS

INFN

금요일 오전 (미 동부 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 크라운 크래프(NASDAQ:CRWS)는 개장 전 4분기 실적을 발표할 예정이다. 크라운 크래프트의 주식은 시간외 거래에서 1% 상승한 5.05달러를 기록했다.

금요일 주목해야 할 주식: 나이키, 인피네라, 노키아 그리고 2종목

Restaurants

After-Hours Center

Movers

Kura Sushi USA, Inc.(NASDAQ:KRUS)가 목요일 애프터마켓에서 2분기 실적을 발표했다. 세부 사항은 다음과 같다. 



주요숫자:  회사는 주당 9센트의 분기 손실을 보고, 이는 분석가들의 3센트의 손실 예상을 하회했다. 분기 매출은 5,729만 달러로 나와, 분석가들의 5,664만 달러의 콘세스 예상을 상회했다. 



&#34;우리의 사업이 끝나지 않는다는 것을 보고해서

쿠라 스시의 2분기 실적: EPS는 예상에 못미치고, 매출은 능가

Kura Sushi USA, Inc. - Class A Common Stock

Kura Sushi USA Inc

Kulicke and Soffa Industries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLIC#NASDAQ">KLIC</a>) shares were rising in early trading on Friday, after <a href="https://www.benzinga.com/quote/KLIC">shedding more than 5% this week</a>.
While reporting earnings, the company announced an order for fluxless TCB from "the world&#8217;s leading foundry," which could be chipmaker Taiwan Semiconductor Mfg. Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), according to Needham.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60ed6112b473c600014bf1c9/charles-shi">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60ed6112b473c600014bf1c9/charles-shi">Charles Shi</a> upgraded the rating for Kulicke and Soffa Industries from Hold to Buy, while establishing a price target of $55.
The Kulicke and Soffa Industries Thesis: Given in order, the company expects TCB revenues to grow by 40%-50% year-on-year in 2025, Shi said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Kulicke and Soffa Industries is expected to generate TCB revenues of around $55 million in 2024, which could now reach as much as $80 million next year, "beating our $70MM estimate by about $10MM," he added.
Rival ASMPT is likely to have failed the TCB qualification at Taiwan Semiconductor and its management said during the third-quarter earnings call that TCB evaluation at the leading foundry "may take another year," the analyst stated.
"To us, the fact that KLIC is already qualified and shipping while ASMPT still has not closed the evaluation means that KLIC has won," he further wrote.
KLIC Price Action: Shares of Kulicke and Soffa Industries rose by 2% to $46.52 at the time of publication on Friday.
Read More: • <a href="https://www.benzinga.com/news/global/24/11/41972365/tsmcs-65b-investment-in-us-will-help-avoid-trade-imbalance-says-taiwan-central-bank-governor-as-trump-returns-to-white-house">TSMC&#8217;s $65B Investment In U.S. Will Help Avoid Trade Imbalance, Says Taiwan Central Bank Governor As Trump Returns To White House</a>
Photo: Screenshot from Kulicke and Soffa video

Analyst Color

Earnings Beats

Long Ideas

Upgrades

Price Target

Analyst Ratings

Tech

KLIC

Kulicke And Soffa Industries Likely To Win Order From Leading Semiconductor Company, Says Bullish Analyst

Macro Economic Events

Market Summary

Economics

General

AMAT

MRNA

Benzinga Market Summary: Vaccine Stocks Fall On Trump's Planned RFK Jr. Nomination To HHS, Applied Materials Stock Falls Following Earnings, Domino's Rises On Berkshire Hathaway Stake

RBC Capital analyst Jimmy Shan maintains Automotive Props REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/APR#TSX">APR</a>) with a Sector Perform and raises the price target from C$12.5 to C$13.

TSX:APR

TSX:APR/UN

RBC Capital Maintains Sector Perform on Automotive Props REIT, Raises Price Target to C$13

UBS analyst Cody Ross maintains Ingredion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>) with a Buy and raises the price target from $165 to $173.

INGR

UBS Maintains Buy on Ingredion, Raises Price Target to $173

Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) is set to lay off nearly 400 employees in Texas, <a href="https://www.benzinga.com/markets/equities/24/08/40335015/exxon-mobil-reduces-staff-after-pioneer-merger-report">following its acquisition</a> of Pioneer Natural Resources earlier this year. 
The downsizing plan includes 376 job cuts in Irving, Texas, and an additional 18 in Midland, according to Reuters, which cited information from the Texas Workforce Commission.
Exxon had extended job offers to almost 1,900 Pioneer employees as part of the merger agreement.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42005094/lenovo-q2-earnings-cloud-momentum-ai-pcs-and-smartphone-growth-drive-revenue-beat" rel="noreferrer noopener">Lenovo Q2 Earnings: Cloud Momentum, AI PCs, And Smartphone Growth Drive Revenue Beat</a>
The company plans to lay off 110 employees by the end of 2024 and schedule another 178 layoffs for 2025. The remaining job cuts, affecting about 100 workers, are expected to occur in 2026.
In line with its focus on shale expansion, Exxon is reportedly preparing to divest conventional oil assets in the Permian Basin valued at <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40596410/exxon-mobil-eyes-permian-assets-sale-to-fuel-shale-expansion-report" rel="noreferrer noopener">approximately $1 billion</a>. The sale would involve mature wells in the Central Basin that provide stable but modest oil output.
For its third quarter, Exxon <a href="https://www.benzinga.com/news/earnings/24/11/41683914/exxon-q3-earnings-11-3-billion-cost-savings-rising-production-dividend-hike-and-more" target="_blank" rel="noreferrer noopener">reported total revenues</a> of $90.02 billion, falling short of the market consensus of $93.94 billion. Production rose by 5%, reaching 4,582 thousand oil-equivalent barrels per day, boosted by increased output from Pioneer's assets. 
Adjusted net profit dropped to $8.61 billion from $9.24 billion in the previous quarter. Exxon achieved structural cost savings of $11.3 billion compared to 2019 levels and aims to reach $15 billion in cumulative savings by the end of 2027.
Exxon Mobil shares have gained 18% year-to-date. However, Viking Fund Management <a href="https://www.benzinga.com/trading-ideas/24/11/41997142/viking-fund-management-sells-big-oil-stocks-in-q3-cuts-tesla-position-in-half-adds-to-largest-position-broadcom" target="_blank" rel="noreferrer noopener">recently reduced its stake</a> in the company.
Price Action: Exxon Mobil stock is up 0.12% at $120.71 at last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41986215/disneys-streaming-profits-and-park-rebound-lead-the-way-analyst" target="_blank" rel="noreferrer noopener">Disney&#8217;s Streaming Profits And Park Rebound Lead The Way: Analyst</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Commodities

Media

Exxon Mobil To Cut 400 Texas Jobs In Stages Through 2026

<a href="https://unemon.com/ResearchEasy/202411_INCY/20241115_INCY_Takeover_POA.html" title="https://unemon.com/ResearchEasy/202411_INCY/20241115_INCY_Takeover_POA.html">https://unemon.com/ResearchEasy/202411_INCY/20241115_INCY_Takeover_POA.html</a>

Rumors

INCY

Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says "Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks"

The cryptocurrency industry is bracing for a potential surge in exchange-traded funds (ETFs) after Donald Trump's election win, signaling what experts believe could be a transformative era for <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40743776/trump-reiterates-plans-to-make-us-world-capital-of-crypto-instead-of-attacking-industries-">digital assets in the U.S</a>.
What Happened: Market participants are hopeful that a pro-crypto Trump administration will end regulatory gridlock and usher in broader approval for innovative crypto-based financial products, <a href="https://www.ft.com/content/6abb3096-e740-4f31-abb5-c0be737f4ae2">according</a> to a Financial Times report.
The Securities and Exchange Commission's (SEC) recent approval of <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42010782/goldman-sachs-expands-bitcoin-etf-holdings-to-710-million">spot Bitcoin</a> and <a href="https://www.benzinga.com/money/what-is-ethereum-etf">Ethereum ETFs</a> marked a significant milestone after years of regulatory pushback.
However, filings for ETFs tied to other digital assets like Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) and Litecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ltc/usd">LTC</a>) have yet to make headway.
Comparatively, Europe has been more accepting, offering exchange-traded products tied to about 30 cryptocurrencies, according to ETFbook data.
Industry leaders are hopeful that Trump's administration will replace SEC Chair Gary Gensler, whose tenure has been marked by strict enforcement actions against the crypto industry. 
Trump has pledged to position the U.S. as a "bitcoin superpower," fueling optimism for more supportive policies.
"This election was a massive win for crypto," said Matt Hougan, Chief Investment Officer of Bitwise Asset Management, which has filed for an XRP ETF. 
"For the past four years, crypto has operated with major regulatory uncertainty. Imagine what happens when those headwinds are removed."
VanEck's head of digital asset research, Matt Sigel, echoed these sentiments, describing the election as a turning point for the crypto industry.
"The SEC's regulation by enforcement approach under Gensler stifled innovation. A return to a disclosure-based system could pave the way for more digital asset ETFs," Sigel noted. 
He expects a <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40470226/solana-etf-approval-in-2024-has-only-a-6-chance-a-snowballs-chance-in-hell-etf-analyst-say">Solana ETF</a> to be trading in the U.S. by the end of next year.
Asset managers are gearing up for what could be a flood of new crypto products. VanEck, buoyed by Trump's victory, has revived its focus on developing digital asset ETFs. 
Canary Capital recently filed for an HBAR ETF, adding to its existing applications for Solana, XRP and Litecoin ETFs.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42007247/bitcoin-dogecoin-success-driven-by-narrative-and-momentum-report-argues">Bitcoin, Dogecoin Success Driven By &#8216;Narrative And Momentum,&#8217; Report Argues</a>
Why It Matters: The market rally following Trump's election has underscored the pent-up demand for crypto innovation.
Solana, XRP and similar tokens have surged by 30% since the results, reflecting optimism for more supportive regulation and the potential approval of exotic crypto ETFs.
In Europe, nearly 30% of the $13 billion market for digital asset ETFs consists of basket products and offerings beyond Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>).
If mirrored in the U.S., these more specialized products could see demand reaching $55 billion, based on ETFbook's projections.
Townsend Lansing, head of product at CoinShares, Europe's largest provider of digital asset ETFs, sees regulatory clarity as crucial for U.S. market growth. 
"A comprehensive legislative regime alongside traditional securities laws is completely missing in the U.S.," Lansing stated. 
He argued for a nuanced approach to regulating cryptocurrencies as commodities or securities, a contentious issue under Gensler's SEC.
While optimism abounds, industry leaders caution that regulatory clarity should not devolve into a "free-for-all." Hougan emphasized the need for balanced oversight, saying, "We want a dialogue-driven approach, not regulatory chaos."
The potential regime change could reposition the U.S. as a global hub for digital assets. Sigel highlighted that over the past four years, the SEC's actions pushed much of the innovation abroad. 
"We're looking forward to the U.S. reclaiming its position as a leader in product development, from ETFs to stablecoins and NFT platforms," he added.
What&#8217;s Next: The impact of these developments will be explored in depth at Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where industry experts will discuss the evolving landscape of crypto regulation and innovation.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/11/41996491/18-republican-states-sue-bidens-sec-over-harsh-crypto-crackdown">18 Republican States Sue Biden&#8217;s SEC Over Harsh Crypto Crackdown</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$LTC

$SOL

$XRP

Solana, Ripple, Litecoin ETFs May Be On The Table Under Trump Administration, Industry Experts Think

RBC Capital analyst Nelson Ng reiterates Boralex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BLX#TSX">BLX</a>) with a Sector Perform and maintains C$38 price target.

Reiteration

TSX:BLX

RBC Capital Reiterates Sector Perform on Boralex, Maintains C$38 Price Target

FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) shares are trading higher after the company disclosed a corporate restructuring <a href="https://www.benzinga.com/pressreleases/24/11/g42005647/fuelcell-energy-announces-global-restructuring-focusing-core-technologies-on-distributed-power-gen" target="_blank" rel="noreferrer noopener">across the U.S., Canada, and Germany</a>.
The goal is to reduce costs and focus on core technologies in response to slower-than-anticipated clean energy investments.
FuelCell Energy expects the restructuring to lower operating costs by approximately 15% in <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">fiscal year 2025 compared to 2024.</a> 
Here&#8217;s the plan:
<ul>
<li>Reduce the workforce by 17% (including actions taken in September)</li>
<li>Slash spending on product development, overhead, and other expenses.</li>
<li>Prioritize commercially available technologies to align with shifting market opportunities.</li>
<li>Expand its Connecticut-made molten carbonate technology (no expected layoffs in Torrington)</li>
<li>Support growing AI-driven data center demands</li>
<li>Address grid deficiencies.</li>
<li>Advance CO2 recovery for industrial uses</li>
<li>Continue developing its joint carbon capture platform, including a demonstration at the Port of Rotterdam. </li>
<li>Grow resources to support its growing South Korean customer base.</li>
</ul>
FuelCell CEO Jason Few said, &#8220;These tailwinds are strengthened by power shortages in grids, high voltage transmission needs, and delays in centralized power projects due to lengthy permitting processes, which our distributed energy platforms do not experience. Additional power demand opportunities are driven by data centers, AI, cryptocurrency growth, more resilient and reliable grids, and carbon recovery and capture.&#8221;
FCEL expects non-recurring charges from the restructuring in Q4 FY2024 and Q1 FY2025 and cash, restricted cash, and short-term investments to exceed $300 million as of Oct. 31.
Investors can gain exposure to the stock via Global X Hydrogen ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYDR#NASDAQ">HYDR</a>).
Price Action: FuelCell shares are up 19.68% at $8.39 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/41926301/sustainable-investment-under-trump-performance-matters-far-more-than-politics-jpmorgan-analyst-says" target="_blank" rel="noreferrer noopener">Sustainable Investment Under Trump: &#8216;Performance Matters Far More Than Politics,&#8217; JPMorgan Analyst Says</a></li>
</ul>
Image: Courtesy of FuelCell Energy

Guidance

Small Cap

FCEL

HYDR

Restructure And Recharge: FuelCell Cuts Workforce, Plans To Reduce Operating Costs By 15% In 2025

UBS analyst Douglas Harter maintains Granite Point Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPMT#NYSE">GPMT</a>) with a Buy and raises the price target from $3.5 to $4.

GPMT

UBS Maintains Buy on Granite Point Mortgage, Raises Price Target to $4

<a href="https://www.bloomberg.com/live/us" title="https://www.bloomberg.com/live/us">https://www.bloomberg.com/live/us</a>

Federal Reserve

Fed's Collins: Not Seeing Evidence Of New Inflation Pressures; The Job Market Looks Like Full Employment Conditions; Sees Healthy Labor Market Conditions; Doesn't See Big Urgency To Lower Rates, But Wants To Preserve Healthy Economy; Won't Speculate About What Trump Will Do On Economy; Tariffs Can Be A Driver Of Inflation

UBS analyst Alex Kramm maintains FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) with a Neutral and raises the price target from $485 to $525.

UBS Maintains Neutral on FactSet Research Systems, Raises Price Target to $525

WIIM

UUUU

Shares of uranium stocks are trading higher following a report suggesting Russia has imposed temporary restrictions on the export of enriched uranium to the US.

Janus Henderson Group plc Ordinary Shares

CORRECTION: Trian 13F Reported No Change In Shares In Janus Henderson Group And General Electric Co.

Whales with a lot of money to spend have taken a noticeably bearish stance on Rivian Automotive.
Looking at options history for Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $846,969 and 5, calls, for a total amount of $266,288.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $2.5 to $20.0 for Rivian Automotive during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Rivian Automotive's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Rivian Automotive's whale activity within a strike price range from $2.5 to $20.0 in the last 30 days. 
<h3>Rivian Automotive Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731684912_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.07</td>
<td>$1.05</td>
<td>$1.06</td>
<td>$11.00</td>
<td>$349.0K</td>
<td>11.8K</td>
<td>3.7K</td>
</tr>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.25</td>
<td>$0.24</td>
<td>$0.25</td>
<td>$7.50</td>
<td>$187.5K</td>
<td>56.7K</td>
<td>806</td>
</tr>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$0.24</td>
<td>$0.23</td>
<td>$0.25</td>
<td>$10.00</td>
<td>$80.7K</td>
<td>21.3K</td>
<td>9.5K</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.24</td>
<td>$1.22</td>
<td>$1.23</td>
<td>$10.00</td>
<td>$79.4K</td>
<td>42.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$0.64</td>
<td>$0.4</td>
<td>$0.57</td>
<td>$10.50</td>
<td>$79.3K</td>
<td>20.9K</td>
<td>3.8K</td>
</tr>
</tbody>
</table>

<h3>About Rivian Automotive</h3>
Rivian Automotive Inc designs, develops, and manufactures category-defining electric vehicles and accessories. In the consumer market, the company launched the R1 platform with the first generation of consumer vehicles: the R1T, a two-row, five-passenger pickup truck, and the R1S, a three-row, seven-passenger sport utility vehicle (SUV).
In light of the recent options history for Rivian Automotive, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Rivian Automotive</h3>
<ul>
<li>Currently trading with a volume of 26,690,067, the RIVN's price is down by -4.07%, now at $9.89. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 96 days.</li>
</ul>
<h3>Professional Analyst Ratings for Rivian Automotive</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $14.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Rivian Automotive, which currently sits at a price target of $12. 
&#x2A; Consistent in their evaluation, an analyst from Guggenheim keeps a Buy rating on Rivian Automotive with a target price of $18. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Neutral rating for Rivian Automotive, targeting a price of $12. 
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on Rivian Automotive, maintaining a target price of $12. 
&#x2A; An analyst from Wedbush downgraded its action to Outperform with a price target of $20. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Rivian Automotive options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

RIVN

Market Whales and Their Recent Bets on RIVN Options

Deep-pocketed investors have adopted a bullish approach towards Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PFE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Pfizer. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 40% bearish. Among these notable options, 10 are puts, totaling $1,248,013, and 10 are calls, amounting to $924,906.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $15.0 to $30.0 for Pfizer over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Pfizer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Pfizer's substantial trades, within a strike price spectrum from $15.0 to $30.0 over the preceding 30 days.
<h3>Pfizer Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731684907_0_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.88</td>
<td>$1.64</td>
<td>$1.7</td>
<td>$26.00</td>
<td>$340.0K</td>
<td>45.2K</td>
<td>2.1K</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$1.63</td>
<td>$1.36</td>
<td>$1.4</td>
<td>$20.00</td>
<td>$283.2K</td>
<td>663</td>
<td>2.0K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$6.25</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$20.00</td>
<td>$256.6K</td>
<td>2.2K</td>
<td>2.0K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.7</td>
<td>$20.00</td>
<td>$170.4K</td>
<td>1.7K</td>
<td>479</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$2.75</td>
<td>$2.63</td>
<td>$2.7</td>
<td>$25.00</td>
<td>$135.0K</td>
<td>35.4K</td>
<td>2.2K</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Having examined the options trading patterns of Pfizer, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Pfizer Standing Right Now?</h3>
<ul>
<li>With a trading volume of 45,749,524, the price of PFE is down by -4.01%, reaching $24.98.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<h3>Expert Opinions on Pfizer</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $36.75.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45. 
&#x2A; In a cautious move, an analyst from Wolfe Research downgraded its rating to Underperform, setting a price target of $25. 
&#x2A; In a cautious move, an analyst from Bernstein downgraded its rating to Market Perform, setting a price target of $32. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Unpacking the Latest Options Trading Trends in Pfizer

In one of the most significant cryptocurrency crime cases to date, Ilya Lichtenstein, who orchestrated the theft of 120,000 bitcoin from Bitfinex in 2016, was sentenced to <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40961791/the-biggest-crypto-crime-cases-in-2024-heists-frauds-and-multi-million-dollar-scams-shake-">five years in prison</a>.
The stolen Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), worth $71 million at the time, is now valued at over $7.6 billion. 
What Happened: Lichtenstein's elaborate laundering <a href="https://storage.courtlistener.com/recap/gov.uscourts.dcd.257739/gov.uscourts.dcd.257739.143.0.pdf">scheme</a>, carried out with the assistance of his wife, Heather Morgan, has been described by authorities as one of the most sophisticated money-laundering operations ever encountered in the cryptocurrency space.
U.S. District Judge Colleen Kollar-Kotelly, delivering the sentence on Thursday, called the theft "meticulously planned" and emphasized the importance of accountability. 
"It's important to send a message that you can't commit these crimes with impunity, that there are consequences to them," she said.
The hack targeted Hong Kong-based exchange Bitfinex, compromising 36% of the company's assets at the time. 
Prosecutors revealed that Lichtenstein spent months infiltrating Bitfinex's infrastructure to execute the theft. After the hack, he moved the stolen Bitcoin through a maze of transactions designed to obscure its origins. 
By 2022, the couple had successfully laundered around 21% of the stolen funds, worth $14 million at 2016 prices, and exceeding $1 billion in 2022.
Heather Morgan, who also faces sentencing, played a lower-level role, according to prosecutors.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/news/legal/24/11/41996491/18-republican-states-sue-bidens-sec-over-harsh-crypto-crackdown">18 Republican States Sue Biden&#8217;s SEC Over Harsh Crypto Crackdown</a>
Initially unaware of the full extent of her husband's actions, she later assisted in laundering the stolen funds.
Authorities recovered over 96% of the stolen bitcoin, valued at over $6 billion, thanks in part to Lichtenstein's cooperation following his arrest in February 2022. 
His defense attorney, Samson Enzer, highlighted this cooperation, stating, "The vast bulk of the stolen money was never spent."
The theft significantly impacted Bitfinex's operations and reputation, forcing the company to take swift action to protect its customers. 
"The hack devastated our finances and reputation," said Barry Berke, an attorney for Bitfinex. 
Despite the setback, Bitfinex absorbed the losses to shield its customers from the fallout.
While in custody, Lichtenstein expressed regret, stating, "I want to take full responsibility for my actions and make amends any way I can." 
He also shared his desire to contribute positively in the future by applying his skills to combat cybercrime.
What&#8217;s Next: The case highlights the need for robust regulatory frameworks and cybersecurity measures to protect digital asset markets, an issue that will be explored at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41993524/gary-gensler-hints-at-ending-his-stint-as-sec-chair-defends-crypto-regulation-agenda">Gary Gensler Hints At Ending His Stint As SEC Chair, Defends Crypto Regulation Agenda</a></li>
</ul>
Image: Shutterstock

Bitcoin Hacker Sentenced To 5 Years For Laundering Billions In Crypto Theft

HSPTU

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals.
Looking at options history for Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 0% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $134,920 and 4, calls, for a total amount of $175,889.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $600.0 and $920.0 for Regeneron Pharmaceuticals, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale activity within a strike price range from $600.0 to $920.0 in the last 30 days. 
<h3>Regeneron Pharmaceuticals 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731684902_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$188.5</td>
<td>$179.3</td>
<td>$185.0</td>
<td>$600.00</td>
<td>$74.0K</td>
<td align="right">5</td>
<td align="right">4</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$155.0</td>
<td>$148.0</td>
<td>$151.0</td>
<td>$920.00</td>
<td>$45.3K</td>
<td align="right">161</td>
<td align="right">3</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$44.2</td>
<td>$38.0</td>
<td>$41.48</td>
<td>$760.00</td>
<td>$41.4K</td>
<td align="right">26</td>
<td align="right">10</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$12.0</td>
<td>$4.8</td>
<td>$8.57</td>
<td>$765.00</td>
<td>$34.2K</td>
<td align="right">0</td>
<td align="right">40</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$118.0</td>
<td>$113.0</td>
<td>$113.0</td>
<td>$850.00</td>
<td>$33.9K</td>
<td align="right">15</td>
<td align="right">3</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
In light of the recent options history for Regeneron Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Regeneron Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>With a trading volume of 189,761, the price of REGN is down by -2.09%, reaching $766.17.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Regeneron Pharmaceuticals</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $1127.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $1260. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Regeneron Pharmaceuticals with a target price of $1065. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Regeneron Pharmaceuticals, targeting a price of $1050. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $1260. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Regeneron Pharmaceuticals with a target price of $1000. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Regeneron Pharmaceuticals with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

REGN

Check Out What Whales Are Doing With REGN

UBS maintains Enbridge (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENB#TSX">ENB</a>) with a Buy and raises the price target from C$63 to C$68.

TSX:ENB

UBS Maintains Buy on Enbridge, Raises Price Target to C$68

Benchmark Co. analyst Todd Brooks maintained a Buy rating on Kura Sushi USA (KRUS – Research Report) today and set a price target of $115.00. The c...

Benchmark Co. Remains a Buy on Kura Sushi USA (KRUS)

Benchmark raised the firm's price target on Kura Sushi (KRUS) to $115 from $90 and keeps a Buy rating on the shares after fiscal Q4 operating resul...

Kura Sushi price target raised to $115 from $90 at Benchmark

Roth MKM raised the firm's price target on Kura Sushi (KRUS) to $120 from $70 and keeps a Buy rating on the shares. The company's fiscal Q4 report ...

Kura Sushi price target raised to $120 from $70 at Roth MKM

Barclays analyst Jeffrey Bernstein raised the firm's price target on Kura Sushi (KRUS) to $90 from $70 and keeps an Equal Weight rating on the shar...

Kura Sushi price target raised to $90 from $70 at Barclays

Kura Sushi USA, Inc. (KRUS) Q4 2024 Earnings Call Transcript

Kura Sushi (KRUS) USA announced that it has commenced an underwritten public offering of shares of its Class A common stock. All shares of Class A ...

Kura Sushi announces offering of Class A common stock, no amount given

William Blair, Barclays and TD Cowen acted as joint book running managers for the offering. Published first on TheFly – the ultimate source for rea...

Kura Sushi 696K share Spot Secondary priced at $85.00

Kura Sushi USA ( ($KRUS) ) has provided an update. Kura Sushi USA, a technology-driven Japanese restaurant brand, is launching an underwritten publ...

Kura Sushi USA Announces Public Offering of Stock

Kura Sushi USA ( ($KRUS) ) has provided an announcement. Kura Sushi USA, Inc., a technology-driven Japanese restaurant chain, successfully closed i...

Comments

Kura Sushi USA

Kura Sushi USA (KRUS) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌